Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
Google Scholar
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Google Scholar
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Google Scholar
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).
Google Scholar
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).
Google Scholar
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Google Scholar
Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines 9, 65 (2021).
Google Scholar
Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710–728 (2019).
Google Scholar
Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, e1805116 (2019).
Google Scholar
Zhang, N. N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271–1283 e1216 (2020).
Google Scholar
McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titres in mice. Nat. Commun. 11, 3523 (2020).
Google Scholar
Pulendran, B., S. Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
Google Scholar
Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e2877 (2021).
Google Scholar
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
Google Scholar
Swaminathan, G. et al. A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Sci. Rep. 6, 34215 (2016).
Google Scholar
Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).
Google Scholar
Ahn, J. & Barber, G. N. STING signaling and host defense against microbial infection. Exp. Mol. Med. 51, 1–10 (2019).
Google Scholar
Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).
Google Scholar
Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509–1519 (2018).
Google Scholar
Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570–1578 (2013).
Google Scholar
Toapanta, F. R. & Ross, T. M. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol. Res. 36, 197–210 (2006).
Google Scholar
Bower, J. F. & Ross, T. M. in Current Topics in Complement 249–264 (Springer, 2006).
Rickert, R. C. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr. Opin. Immunol. 17, 237–243 (2005).
Google Scholar
Phua, K. K. L., Staats, H. F., Leong, K. W. & Nair, S. K. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci. Rep. 4, 5128 (2014).
Google Scholar
Mai, Y. et al. Intranasal delivery of cationic liposome–protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell. Immunol. 354, 104143 (2020).
Google Scholar
Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021).
Google Scholar
Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. Nat. Med. 27, 78–85 (2021).
Google Scholar
Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462 (2020).
Google Scholar
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 e1415 (2020).
Google Scholar
Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
Google Scholar
Oberhardt, V. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature 597, 268–273 (2021).
Google Scholar
Reinscheid, M. et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat. Commun. 13, 4631 (2022).
Google Scholar
Liu, J. et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci. Immunol. 7, eabq7647 (2022).
Google Scholar
Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. Cell 185, 847–859 e811 (2022).
Google Scholar
Mise-Omata, S. et al. Memory B cells and memory T cells induced by SARS-CoV-2 booster vaccination or infection show different dynamics and responsiveness to the omicron variant. J. Immunol. 209, 2104–2113 (2022).
Google Scholar
Dhawan, M. et al. Updated insights into the T cell-mediated immune response against SARS-CoV-2: a step towards efficient and reliable vaccines. Vaccines 11, 101 (2023).
Google Scholar
Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186–193 (2022).
Google Scholar
Richardson, S. J., Bai, A., Kulkarni, A. A. & Moghaddam, M. F. Efficiency in drug discovery: liver S9 fraction assay as a screen for metabolic stability. Drug Metab. Lett. 10, 83–90 (2016).
Google Scholar
Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Google Scholar
Li, B., Luo, X. & Dong, Y. Effects of chemically modified messenger RNA on protein expression. Bioconjug. Chem. 27, 849–853 (2016).
Google Scholar
Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).
Google Scholar
Miao, L. et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun. 11, 2424 (2020).
Google Scholar
vander Straeten, A. et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01774-z (2023).
Google Scholar
Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017).
Google Scholar
Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. eBioMedicine 76, 103841 (2022).
Google Scholar
Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01679-x (2023).
Google Scholar
Ndeupen, S. et al. The mRNA–LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).
Google Scholar
Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46–61 (2017).
Google Scholar
Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508–1519.e1512 (2020).
Google Scholar
Kaplonek, P. et al. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Sci. Immunol. 6, eabj2901 (2021).
Google Scholar
Kaplonek, P. et al. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity 55, 355–365.e354 (2022).
Google Scholar
Harrod, K. et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE 16, e0253487 (2021).
Google Scholar
Rosenblum, H. G. et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect. Dis. (2022).
Bastard, P., Zhang, Q., Zhang, S. Y., Jouanguy, E. & Casanova, J. L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr. Opin. Immunol. 74, 172–182 (2022).
Google Scholar
Hervas-Stubbs, S. et al. Effects of IFN-alpha as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells. Eur. J. Immunol. 40, 3389–3402 (2010).
Google Scholar
Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 169, 176 (2017).
Google Scholar
Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 21, 39–51 (2021).
Google Scholar
Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348–350 (1996).
Google Scholar
Ross, T. M., Xu, Y., Bright, R. A. & Robinson, H. L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1, 127–131 (2000).
Google Scholar
Bower, J., Sanders, K. & Ross, T. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr. HIV Res. 3, 191–198 (2005).
Google Scholar
Green, T. D. et al. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20, 242–248 (2001).
Google Scholar
He, Y. G. et al. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology 223, 125–134 (2018).
Google Scholar
Zhang, D. et al. Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus. Vaccine 29, 629–635 (2011).
Google Scholar
Green, T. D., Montefiori, D. C. & Ross, T. M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77, 2046–2055 (2003).
Google Scholar
Watanabe, I. et al. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21, 4532–4538 (2003).
Google Scholar
Yang, S. et al. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization. Virus Res. 151, 162–169 (2010).
Google Scholar
Wang, L., Sunyer, J. O. & Bello, L. J. Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J. Virol. 78, 1616–1622 (2004).
Google Scholar
Zhang, Z. et al. Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus. Virol. J. 7, 89 (2010).
Google Scholar
Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020).
Google Scholar
Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).
Google Scholar
Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).
Google Scholar
Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9–16 (2017).
Google Scholar
Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97–108 (2018).
Google Scholar
Morabito, K. M. et al. Memory inflation drives tissue-resident memory CD8+ T cell maintenance in the lung after intranasal vaccination with murine cytomegalovirus. Front. Immunol. 9, 1861 (2018).
Google Scholar
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
Google Scholar
Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).
Google Scholar
Künzli, M. et al. Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells. Sci. Immunol. 7, eadd3075 (2022).
Google Scholar
Vaca, G. B. et al. Intranasal mRNA–LNP vaccination protects hamsters from SARS-CoV-2 infection. Preprint at bioRxiv (2023).
Boudreau, C. M. & Alter, G. Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine. Front. Immunol. 10, 440 (2019).
Google Scholar
Meyer, M. et al. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Sci. Transl. Med. 13, eabg6128 (2021).
Google Scholar
Neidich, S. D. et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J. Clin. Invest. 129, 4838–4849 (2019).
Google Scholar
Zohar, T. et al. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host Microbe 30, 41–52.e45 (2022).
Google Scholar
Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465–470 (2021).
Google Scholar
Puntel, M. et al. Identification and visualization of CD8+ T cell mediated IFN-gamma signaling in target cells during an antiviral immune response in the brain. PLoS ONE 6, e23523 (2011).
Google Scholar
Kim, P. S. & Ahmed, R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22, 223–230 (2010).
Google Scholar
Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004).
Google Scholar
Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204, 845–853 (2011).
Google Scholar
Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276–287 (2005).
Google Scholar
Shobaki, N., Sato, Y. & Harashima, H. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting. Int. J. Nanomed. 13, 8395–8410 (2018).
Google Scholar
Chen, X., Gentili, M., Hacohen, N. & Regev, A. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies. Nat. Commun. 12, 5506 (2021).
Google Scholar